CA3003262C - Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation - Google Patents
Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation Download PDFInfo
- Publication number
- CA3003262C CA3003262C CA3003262A CA3003262A CA3003262C CA 3003262 C CA3003262 C CA 3003262C CA 3003262 A CA3003262 A CA 3003262A CA 3003262 A CA3003262 A CA 3003262A CA 3003262 C CA3003262 C CA 3003262C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- galr2
- acid sequence
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne un agoniste du récepteur de type 2 de la galanine basé sur la spexine, et une utilisation de ce dernier. Plus particulièrement, la présente invention concerne un agoniste peptidique présentant une spécificité et stabilité améliorées vis-à-vis du récepteur de type 2 de la galanine, l'agoniste peptidique étant impliqué dans la régulation de fonctions physiologiques de l'organisme dans lesquelles le récepteur de type 2 de la galanine joue un rôle, telles que l'alimentation, l'anxiété, l'émotion et l'addiction, permettant de ce fait de supprimer l'appétit, de soulager des troubles anxieux, et de diminuer l'addiction au plaisir, et, en conséquence, l'agoniste peptidique peut être utilisé pour prévenir ou traiter des maladies induites par le récepteur de type 2 de la galanine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0168555 | 2015-11-30 | ||
KR1020150168555A KR101885238B1 (ko) | 2015-11-30 | 2015-11-30 | 스펙신 기반 갈라닌 2형 수용체의 효현제 및 이의 용도 |
PCT/KR2016/013950 WO2017095132A1 (fr) | 2015-11-30 | 2016-11-30 | Agoniste du récepteur de type 2 de la galanine basé sur la spexine, et utilisation de ce dernier |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3003262A1 CA3003262A1 (fr) | 2017-06-08 |
CA3003262C true CA3003262C (fr) | 2023-10-31 |
Family
ID=58797220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3003262A Active CA3003262C (fr) | 2015-11-30 | 2016-11-30 | Agonistes de recepteur de type 2 de la galanine bases sur la spexine et leur utilisation |
Country Status (9)
Country | Link |
---|---|
US (3) | US10385098B2 (fr) |
EP (1) | EP3384920A4 (fr) |
JP (1) | JP6619097B2 (fr) |
KR (1) | KR101885238B1 (fr) |
CN (1) | CN108348570B (fr) |
AU (2) | AU2016361783C1 (fr) |
BR (1) | BR112018008315A2 (fr) |
CA (1) | CA3003262C (fr) |
WO (1) | WO2017095132A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022287A (en) | 1998-08-19 | 2000-02-08 | General Motors Corporation | Modularly constructed vehicular transmission |
KR101885238B1 (ko) | 2015-11-30 | 2018-08-06 | 주식회사 뉴라클사이언스 | 스펙신 기반 갈라닌 2형 수용체의 효현제 및 이의 용도 |
EP3645040A4 (fr) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers |
CN111154712B (zh) * | 2020-01-10 | 2022-02-08 | 复旦大学附属华山医院 | 一种Spexin促进胰岛素的分泌和胰岛细胞增殖的方法 |
CN116751261B (zh) * | 2023-06-29 | 2024-05-14 | 湖南中晟全肽生物科技股份有限公司 | 一种galr2激动剂及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972624A (en) * | 1996-01-24 | 1999-10-26 | Synaptic Pharmaceutical Corporation | Method of identifying ligands which bind recombinant galanin receptor (GALR2) |
GB0403509D0 (en) * | 2004-02-17 | 2004-03-24 | Neuro Targets Ltd | Galanin receptors and brain injury |
EP1978987B1 (fr) * | 2006-01-05 | 2014-12-31 | University of Utah Research Foundation | Procedes et compositions associees pour l'amelioration de proprietes d'agents pharmacologiques ciblant le systeme nerveux |
EP2622351B1 (fr) | 2010-09-28 | 2014-08-27 | Actelion Pharmaceuticals Ltd. | Neuropeptide q utilisé comme modulateur de gpcr galr2 et ses utilisations |
WO2012051567A2 (fr) * | 2010-10-15 | 2012-04-19 | The Trustees Of Columbia University In The City Of New York | Gènes de l'obésité, leurs protéines et leurs utilisations |
WO2012051657A1 (fr) | 2010-10-20 | 2012-04-26 | Poolrite Research Pty Ltd | Procédé de désinfection de l'eau |
US9556242B2 (en) | 2011-01-24 | 2017-01-31 | Anygen Co., Ltd. | Method for regulating circadian rhythms |
KR101885238B1 (ko) | 2015-11-30 | 2018-08-06 | 주식회사 뉴라클사이언스 | 스펙신 기반 갈라닌 2형 수용체의 효현제 및 이의 용도 |
-
2015
- 2015-11-30 KR KR1020150168555A patent/KR101885238B1/ko active IP Right Grant
-
2016
- 2016-11-30 JP JP2018523789A patent/JP6619097B2/ja active Active
- 2016-11-30 AU AU2016361783A patent/AU2016361783C1/en active Active
- 2016-11-30 WO PCT/KR2016/013950 patent/WO2017095132A1/fr active Application Filing
- 2016-11-30 CA CA3003262A patent/CA3003262C/fr active Active
- 2016-11-30 CN CN201680062527.4A patent/CN108348570B/zh active Active
- 2016-11-30 BR BR112018008315-1A patent/BR112018008315A2/pt active Search and Examination
- 2016-11-30 EP EP16871028.3A patent/EP3384920A4/fr active Pending
- 2016-11-30 US US15/771,078 patent/US10385098B2/en active Active
-
2019
- 2019-04-26 AU AU2019202918A patent/AU2019202918B2/en active Active
- 2019-07-15 US US16/511,976 patent/US11248023B2/en active Active
-
2022
- 2022-01-19 US US17/579,463 patent/US20220242910A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11248023B2 (en) | 2022-02-15 |
CA3003262A1 (fr) | 2017-06-08 |
US20200010509A1 (en) | 2020-01-09 |
US20220242910A1 (en) | 2022-08-04 |
US10385098B2 (en) | 2019-08-20 |
KR20170062848A (ko) | 2017-06-08 |
WO2017095132A1 (fr) | 2017-06-08 |
AU2019202918B2 (en) | 2020-04-30 |
AU2019202918A1 (en) | 2019-05-16 |
EP3384920A4 (fr) | 2019-05-08 |
EP3384920A1 (fr) | 2018-10-10 |
AU2016361783C1 (en) | 2019-06-06 |
JP6619097B2 (ja) | 2019-12-11 |
CN108348570A (zh) | 2018-07-31 |
KR101885238B1 (ko) | 2018-08-06 |
CN108348570B (zh) | 2022-05-03 |
US20180319841A1 (en) | 2018-11-08 |
BR112018008315A2 (pt) | 2018-10-30 |
AU2016361783A1 (en) | 2018-05-10 |
AU2016361783B2 (en) | 2019-02-07 |
JP2018537444A (ja) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11248023B2 (en) | Agonist of spexin-based galanin type 2 receptor and use thereof | |
Garnham et al. | The chemical complexity of cellular microtubules: tubulin post‐translational modification enzymes and their roles in tuning microtubule functions | |
EP3577462B1 (fr) | Interaction entre les peptides-c et le récepteur de l'elastine, un modèle pour comprendre la maladie vasculaire | |
US20100105625A1 (en) | Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders | |
Lamothe et al. | Chapter five-ubiquitination of ion channels and transporters | |
JP7009364B2 (ja) | ホモシスチン尿症の治療する組成物および方法 | |
CN114026114A (zh) | 用于治疗再灌注损伤的bnip3肽 | |
AU2012272550B2 (en) | Prevention and treatment of acute inflammatory conditions | |
US20150087604A1 (en) | Anti-fatty acid synthase polypeptide and use thereof | |
JP2010229093A (ja) | 新規ChemerinRアゴニスト | |
KR101885241B1 (ko) | 스펙신 기반 갈라닌 2형 수용체의 효현제 및 이의 용도 | |
WO2008111063A2 (fr) | Régulation de la séquestration et de la libération des neurotransmetteurs par manipulation des fonctions vésiculaires | |
WO2012006640A2 (fr) | Compositions et procédés utiles dans la stimulation de la mémoire | |
JP2021020900A (ja) | 糖代謝異常改善剤 | |
US10247735B2 (en) | Compositions and methods for regulating glucose metabolism | |
WO2014014819A2 (fr) | Méthodes de traitement de troubles du métabolisme du glucose | |
WO2006070804A1 (fr) | Procede inhibant l’activite de la telomerase et inhibiteur | |
WO2024102077A1 (fr) | Compositions et méthodes pour le traitement de l'obésité | |
US20030027171A1 (en) | Cell cycle regulator protein | |
Tang et al. | The glycogen cargo receptor STBD1: from biology to disease targeted therapies | |
De Francesco | Structural and functional mechanisms of Aceruloplasminemia | |
TW201234009A (en) | Pharmaceutical composition of regulating the expression level of survival of motor neuron 1 and method of detecting enzyme activity of ubiquitin carboxyl-terminal hydrolase L1 in human fibroblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |
|
EEER | Examination request |
Effective date: 20180425 |